Recurrence of persistent polyclonal B lymphocytosis (PPBL) after rituximab treatment

Ann Hematol. 2015 Jun;94(6):1075-6. doi: 10.1007/s00277-015-2302-6. Epub 2015 Feb 1.

Authors

C Wehr¹, L Houet, M Pantic, S Gutenberger, F Emmerich, R Marks, P Fisch, Klaus Warnatz

Affiliation

¹ Center for Chronic Immunodeficiency (CCI), University Medical Center Freiburg, University of Freiburg, Breisacherstrasse 117, 79106, Freiburg, Germany.

PMID: 25638669
DOI: 10.1007/s00277-015-2302-6

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Antibodies, Monoclonal, Murine-Derived / therapeutic use*
Female
Humans
Immunologic Factors / therapeutic use*
Lymphocytosis / diagnosis*
Lymphocytosis / drug therapy*
Recurrence
Rituximab
Treatment Outcome

Substances

Antibodies, Monoclonal, Murine-Derived
Immunologic Factors
Rituximab

Supplementary concepts

Persistent Polyclonal B-Cell Lymphocytosis